Mechanisms and clinical impact of antifungal drug resistance
H. Vanden Bossche(Janssen (Belgium)), O. Ronin(Institut Pasteur), D. Kerridge(University of Cambridge), Patrick Marichal(Institut Pasteur), L. Improvisi(Institut Pasteur), B. Dupont(Délégation Paris 5), Soma Sen Gupta(Janssen (Belgium)), Frank C. Odds(Radboud University Nijmegen), F. Provost(Institut Pasteur), David W. Warnock(University of Alabama at Birmingham)
Cited by 132
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
|Clinical Infectious Diseases|1997|863
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007
|Clinical Microbiology and Infection|2011|752
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
|Clinical Infectious Diseases|2003|680